Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Mike Quigley (Democrat) · Sponsor of record · Official record ↗
- What it does
- The bill would reauthorize the Accelerating Access to Critical Therapies for ALS Act through fiscal year 2031, extending federal grants for research on ALS therapies that would otherwise expire after 2026. It would also require grant applicants seeking renewals to submit enrollment, safety, and efficacy data for review, obligate grant recipients to promptly report new serious adverse events from their trials, count combined phase 2/3 trials as eligible if they begin enrollment within a timeframe the Secretary sets, and direct the FDA to publish a rare neurodegenerative disease action plan within 18 months plus a follow-up report within 5 years. This bill reauthorizes federal ALS research grants through fiscal year 2031, funding research institutions and contract labs, while requiring grant recipients to meet stricter safety reporting and data review rules.
- Where it stands
- HR8205 has cleared Congress: the House passed it by voice vote under suspension of the rules on July 22, 2026, and the Senate passed the House text without amendment by voice vote on September 28, 2026, so both chambers have agreed to identical text. It is no longer pending before any committee or either chamber, and the record shows no presentment yet.